It has a role as a prognostic biomarker in predicting the risk of recurrence at ten years and benefits from chemotherapy in ER-positive, HER2-negative breast cancer with 0–3 positive lymph nodes (N0-N1) [91]. This evidence concerns the gene ERBB2 and breast carcinoma.